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Abstract
Background: The use of electronic patient records for assessing outcomes in clinical trials is a methodological
strategy intended to drive faster and more cost-efficient acquisition of results. The aim of this manuscript was to
outline the data collection and management considerations of a maternity and perinatal clinical trial using data
from electronic patient records, exemplifying the DESiGN Trial as a case study.
Methods: The DESiGN Trial is a cluster randomised control trial assessing the effect of a complex intervention
versus standard care for identifying small for gestational age foetuses. Data on maternal/perinatal characteristics
and outcomes including infants admitted to neonatal care, parameters from foetal ultrasound and details of
hospital activity for health-economic evaluation were collected at two time points from four types of electronic
patient records held in 22 different electronic record systems at the 13 research clusters. Data were pseudonymised
on site using a bespoke Microsoft Excel macro and securely transferred to the central data store. Data quality
checks were undertaken. Rules for data harmonisation of the raw data were developed and a data dictionary
produced, along with rules and assumptions for data linkage of the datasets. The dictionary included descriptions
of the rationale and assumptions for data harmonisation and quality checks.
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Results: Data were collected on 182,052 babies from 178,350 pregnancies in 165,397 unique women. Data
availability and completeness varied across research sites; each of eight variables which were key to calculation of
the primary outcome were completely missing in median 3 (range 1–4) clusters at the time of the first data
download. This improved by the second data download following clarification of instructions to the research sites
(each of the eight key variables were completely missing in median 1 (range 0–1) cluster at the second time point).
Common data management challenges were harmonising a single variable from multiple sources and categorising
free-text data, solutions were developed for this trial.
Conclusions: Conduct of clinical trials which use electronic patient records for the assessment of outcomes can be
time and cost-effective but still requires appropriate time and resources to maximise data quality. A difficulty for
pregnancy and perinatal research in the UK is the wide variety of different systems used to collect patient data
across maternity units. In this manuscript, we describe how we managed this and provide a detailed data dictionary
covering the harmonisation of variable names and values that will be helpful for other researchers working with
these data.
Trial registration: Primary registry and trial identifying number: ISRCTN 67698474. Registered on 02/11/16.
Keywords: Data management, Data linkage, Methodology, Electronic patient records, Cluster randomised trial,
Perinatal, Maternal
Background
Electronic patient record (EPR) systems, also known as
electronic medical records, store data that are routinely
recorded during the course of normal clinical investiga-
tion and management, for the purpose of documenting
the events of the patient visit. In the UK, EPR systems
store relevant data on patients’ demographics, medical
and surgical history and records of consultations which
have occurred with any healthcare provider at the site at
which the record is stored. EPR systems may also store
appointment or admission data, medication history or a
record of investigations, although different specialist sys-
tems are often used for different types of data or clinical
tasks (e.g. prescribing, or reporting on radiographic
investigations).
The use of EPR data for analysis in clinical trials is a
strategy intended to support more cost- and time-
efficient trials [1]. Whilst there are many examples of
national epidemiological research and audit conducted
using EPR data over the past 20 years [2], clinical trials
using data collected from EPR have only become more
prevalent in the last 5 years. Examples in maternal and
perinatal medicine come from Canada [3], Sweden [4],
the Netherlands [5], Scotland [6, 7], Wales [8] and Eng-
land [9, 10].
The DESiGN (DEtection of the Small for GestatioNal
age fetus) Trial is a cluster randomised control trial
which used data primarily from EPR to test the clinical
impact and cost-effectiveness of a complex antenatal
intervention [10]. This approach was chosen as a cost-
and time-effective, feasible method to collect data on
baseline characteristics, and primary and secondary clin-
ical and economic outcomes of approximately 180,000
births at 13 cluster sites over the 3-year data collection
period. The trial was closed following completed follow-
up of outcomes in February 2019.
The aim of this manuscript was to outline the data
collection and management considerations of a mater-
nity and perinatal clinical trial using EPR data, exempli-




The aim of the DESiGN trial is to test the clinical effect-
iveness and cost efficacy of the Growth Assessment
Protocol (GAP) [11], compared with standard practice,
to accurately detect small for gestational age (SGA) foe-
tuses. It will also assess secondary clinical outcomes,
cost-effectiveness and, as part of a process evaluation,
the implementation of the GAP.
Cluster randomisation was chosen because the inter-
vention required implementation at the maternity unit
level. It required staff training and implementation of
protocols across the site. The designated clusters were
maternity units. Pregnant women being cared for in each
maternity unit were expected to be exposed to the inter-
vention or standard treatment, as per allocation arm.
The primary outcome was antenatal ultrasound detec-
tion of SGA in babies found to be SGA at birth. Second-
ary outcomes included maternal labour and birth
outcomes, neonatal outcomes, implementation outcomes
and an economic evaluation of the intervention cost-
effectiveness. The full protocol of the study has been
published previously [10].
From the outset of this trial, data collection was
planned to use downloaded reports from established
EPR systems holding maternal, foetal and/or neonatal
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data, including foetal measurements taken at ultrasound
and hospital administrative data on inpatient admissions
and outpatient appointments. Data were required from
three trial phases: for 1 year pre-randomisation (to study
baseline characteristics and use these to adjust outcomes
across clusters), implementation washout (a variable
time period during which the sites allocated to the inter-
vention were preparing for and implementing the inter-
vention), trial comparison phase (a 4–6-month period
during which all births in a site contributed to the pri-
mary analysis of the trial outcomes and the care contin-
ued as allocated).
All data management for this trial was conducted using
StataIC v15 (StataCorp LP, College Station, Texas). The full
data management process has been summarised in Fig. 1.
Ethical review
Ethical review of the protocol was conducted by the
Bloomsbury Research Ethics Council (Ref: 12/LO/1632)
and UK Confidentiality Advisory Group (CAG Ref: 12/
CAG/0195). Ethical review by CAG was required for the
use of women’s EPR data without direct consent (opt-out
basis) and so that the research team were able to access
patient-identifiable data at the clinical research sites. This
was essential for accurate linkage of data from different
EPR systems, through pseudonymisation processes.
Data acquisition
Data were required from four types of EPR system: (i)
data on maternal/perinatal characteristics and outcomes
(maternity EPR), (ii) data on characteristics and out-
comes of infants admitted to neonatal care (neonatal
EPR), (iii) data on timing and findings of antenatal ultra-
sound scans (ultrasound EPR) and (iv) data on hospital
activity, e.g. number of antenatal clinic visits (hospital
administrative EPR). These data were collected at two
time points from a key point of contact (usually a re-
search midwife) at the 13 cluster sites. Data were re-
quested in Microsoft Excel spreadsheets. The first
request was initiated in January 2018 for data on births
during the 1 year prior to randomisation of sites into the
trial, to allow for data quality checks and troubleshoot-
ing prior to the subsequent request. The second request
was initiated in March 2019. This request was for a re-
run of any data download for the pre-randomisation
phase that had been amended following resolution of
quality issues from the first request and for data from
the implementation washout and trial comparison
phases. The types of data and expected source EPR sys-
tem at each site are summarised in Fig. 2. The maternity
EPR acted as a spine onto which the other three data
types were to be linked (Fig. 3).
Since the neonatal data were expected to come from
the same EPR software (CleverMed Badgernet Neonatal)
in all units, a data extraction tool was built, specific to
that software (the code is available in Additional File 1).
This was intended to assist the site clinicians in quickly
extracting the relevant neonatal data for the study. It
was also possible to share pre-built data extraction tools
for two of the ultrasound EPR software types (View-
point, GE Healthcare and Astraia).
Pseudonymisation
Data provided by the maternity sites included patient
identifiers: National Health Service (NHS) patient number,
hospital patient number, date of birth (DOB) and post-
code. Patient identifiers were required so that a unique
study identifier (ID) could be generated for each woman
in the study across all linked datasets, using a pseudony-
misation tool.
The pseudonymisation tool was developed by the re-
search team as an Excel macro using Microsoft Visual
Basic for Applications and refined and tested using sim-
ulated data in Stata v15 to prevent generation of dupli-
cate study identifiers. The simulation dataset included
fictitious NHS numbers and DOB for women, and dates
of delivery (DOD) for the infants. All simulated women
had DOB between 1 January 1989 and 31 December
1990 and DOD between 1 January 2017 and 30 Novem-
ber 2018. Narrow date ranges were chosen to increase
the number of duplicate dates and therefore test the risk
that different women could be allocated the same study
ID.
On site, the pseudonymisation procedure was con-
ducted by the trial clinical fellow and data manager,
under the supervision of the cluster’s key clinical con-
tact, in keeping with ethical approval for data flow. A
manually produced pseudonym was generated if a
woman did not have any of the variables needed by the
pseudonymisation tool.
The algorithm for the pseudonymisation tool cannot
be shared because of the risk of de-anonymisation.
Data extraction and storage
Following generation of a pseudonymised ID, the women’s
DOB were also used to calculate their age at delivery of
the neonate and their postcodes were used to generate
measures of socioeconomic deprivation (index of multiple
deprivation, lower layer and middle layer super output
areas) using the National Statistics Postcode look-up ta-
bles [12]. Following this, all identifiable data (NHS/hos-
pital numbers, maternal DOB and postcodes) were
removed from the pseudonymised dataset.
The pseudonymised ID allowed early linkage between
the four datasets. Women and babies who featured in
the neonatal, ultrasound or activity datasets, but did not
have a record of a birth in the maternity dataset were
identified and removed from these three datasets. Later
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linkage was conducted to link unique pregnancies across
the four datasets, for women who had more than one
pregnancy during the study period.
All pseudonymised datasets were checked for absence of
patient identifiers by the trial research fellow (SR), trial
data manager (ME) and local clinical contact before the
data were electronically transferred back to the central re-
search site using NHS Digital’s secured email system,
NHSmail [13], and stored on the servers based at King’s
College London. The keys linking the newly generated
study ID with the women’s identifiers were left with the
clinical contact, to be stored for a minimum of 5 years.
Initial assessment of data quality and completeness
The data collected at the first download (for the pre-
randomisation trial phase) underwent the following
checks for completeness and plausibility:
Fig. 1 Flowchart of the summarised data management process
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 Presence of all four requested datasets
(maternity, neonatal, ultrasound and activity
data).
 Duplication of study IDs includes assessment of
whether these were true duplicates, or the same
woman with multiple birth(s).
 Matching of study IDs across the 4 datasets, i.e. how
many of the study IDs from the maternal data
appeared in the linked datasets.
 Presence of the requested variables in the dataset
 Level of completeness of the requested variables
 Range, median, 5th, 25th, 75th and 95th centile of
the continuously reported variables, e.g. maternal
age, height, weight.
 Date range of all reported births and hospital
activities—checking these were within the requested
timeframe.
Where data quality issues could be rectified, these
were addressed with the cluster site before the second
data download. If data quality issues could not be re-
solved, these were recorded.
Fig. 2 Expected data types and sources
Fig. 3 Planned linkage of the four datasets
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The second data download was then subject to a lim-
ited data quality checklist (it was assumed that the data
quality had not deteriorated since the first download):
 Resolution of any data quality issues raised from
data quality checks on the data downloaded
following the first request
 Assessment for duplicate study IDs
 Completeness of the variables which are key to the
calculation of the trial primary outcome.
 Distribution of the continuous variables required to
calculate the primary outcome (as per assessment of
numerical distribution above)
 Value responses to categorical variables required to
calculate the primary outcome
 Date range of all reported births and hospital
activity data
Data harmonisation
In order to harmonise the four datasets from the differ-
ent EPR systems, a data dictionary was developed using
the list of requested variables. This was intended to
guide the data management team in the harmonisation
process by listing the abbreviated and full variable
names, a description of the variable and, for each re-
search cluster, a guide to the re-categorisation of textual
data (e.g. mode of birth) or re-calculation of units for
numerical data. The full data dictionary can be viewed
in Additional File 2.
A standardised nomenclature (Fig. 4) was used for the
abbreviated variable names to identify the source of the
data (e.g. maternal or neonatal EPR systems) and the de-
gree of data management which had been done to the
variable (e.g. raw, harmonised or calculated variable).
For continuous numerical variables, guidance was pro-
vided on the appropriate units to use, and how to calcu-
late where necessary (e.g. if height was provided in feet
and inches, it was converted to metres and then used to
calculate body mass index, BMI).
For categorical variables, guidance was produced for
each site on how to change the variable to the harmo-
nised version (e.g. how to merge the multiple descrip-
tions of mode of birth into three categories: unassisted
vaginal birth, assisted vaginal birth and caesarean sec-
tion). The way in which text responses to categorical (or
free text) variables were to be (re)categorised was de-
cided in advance by consensus of the clinicians in the re-
search team, following both familiarisation of the early
datasets and consideration of what categories would be
useful for the final planned analyses. Where possible,
variables were re-categorised as binary, e.g. pre-existing
hypertension: ‘yes’/‘no’. In all cases, but particularly im-
portant where it was not possible to re-categorise a vari-
able according to the pre-planned categories, the raw
data were also kept in the final dataset. The main clinical
research team (SR, MCV, DP) familiarised themselves
with the available data formats and agreed rules for data
harmonisation through consensus, in advance of the ac-
tive data management processes.
 Within any cluster’s dataset, if only an affirmative
value is recorded for a binary variable (e.g. presence
or absence of chronic hypertension), the missing
values were treated as negatives (i.e. no
hypertension) and changed to values which reflected
this. We assumed that only the affirmative option
was available to the person who entered the data.
 Where negative values were recorded as well as
affirmative, missing values were left missing
Fig. 4 Standardised nomenclature for data dictionary
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during data management. For some instances
however, the proportion of affirmative values in
the cluster was close to the proportion expected
following comparison with national audit results
from the same period [14] (e.g. for severe
perineal trauma) suggesting missing values would
almost always be negative. These missing values
were not imputed and were subsequently treated
as negative in analysis.
 Within any dataset, where data for clinical diagnoses
or events were available from more than one raw
source, any record of the value was regarded as it
being positive, even if it was not recorded as positive
elsewhere. For example, where a woman was
recorded as having an epidural in the ‘labour
anaesthesia’ variable but this was not recorded in
the ‘birth anaesthesia’ variable (both from the
maternity dataset), she was regarded as having had
an epidural.
Harmonisation was an iterative process. Initially, only
data derived from maternity EPR were harmonised. The
harmonised maternity dataset (one per hospital) were
then checked for adherence to the data dictionary and
data management rules by a member of the clinical
study team. Where errors were made, the clinician con-
ducting the harmonisation checks sent a written list of
required edits to the data management team, who
effected the changes. This meant that a clear audit trail
was in place for changes to the data. The same process
was then repeated for the updated versions of the mater-
nity datasets and for the ultrasound, neonatal and activ-
ity datasets, until the clinician was satisfied with the final
datasets.
Data linkage for the linkage of unique pregnancies
Data linkage to match data for the same pregnancy or
infant from the neonatal, ultrasound and activity data-
sets with the correct woman and birth in the maternal
dataset (some women had more than one pregnancy or
baby) was conducted using the pseudonyms generated at
data collection and the following rules, by adding a ‘_n’
suffix to the study ID (where ‘n’ refers to the nth preg-
nancy at a particular site during the whole trial period
for the woman with that study ID):
 The neonates in the neonatal EPR were matched to
the correct mother and pregnancy in the maternal
EPR system using (i) the maternal study ID (present
in both datasets) and (ii) the neonatal date of birth
within 7 days of the mother’s date of delivery.
 The hospital activity within the administrative
dataset was matched to the appropriate mother and
pregnancy using (i) the maternal study ID (present
in both datasets) and (ii) the timing of the
appointment or admission: this was required to fall
between the estimated date of conception (EDC =
date of delivery − gestational age at birth + 14 days)
and the date of delivery. For this trial, we were not
collecting data on postnatal readmissions.
 The ultrasound scans within the ultrasound dataset
were matched to the correct mother and pregnancy
using (i) the maternal study ID (present in both
datasets) and (ii) the timing of the ultrasound scan:
this was required to fall between the EDC and the
date of delivery.
Assessing data quality in the linked dataset
Quantitative variables were assessed according to an
outlier policy. We calculated the 3rd, 4th and 5th stand-
ard deviation limits and the 1st and 99th centiles in the
data distribution for each continuous variable. These
were used to highlight possible implausible values that
were likely erroneous data entries. However, these distri-
butional cut-points are arbitrary and are also influenced
by whether the variable has an (approximate) normal
distribution. Simply removing variables beyond these
limits could result in accurate data being removed.
These limits were therefore used as indicators of poten-
tial erroneous values and the final outlier limits were de-
rived following clinician consensus on values which were
sensible (Table 1). Values outside the outlier limits were
converted to missing.
Summary statistics, including variable completeness
for key sociodemographic, clinical and outcome variables
were produced. Data quality was compared across sites
and timepoints.
Managing missing data
Missing values were multiply imputed through chained
equations (MICE) with 10 imputations under the
missing-at-random assumption [15]. A common set of
predictors was chosen to predict missing values in each
variable, each chosen because it was expected to be a
good predictor of most if not all the variables and
Table 1 Outlier limits derived following clinical consensus
Lower limit Upper limit
Maternal age at delivery (years) 13y 60y
Height (cm) 120 cm 200 cm
Weight (kg) 30 kg 200 kg
BMI (kg/m2) 13 kg/m2 70 kg/m2
EBL (mL) 1 mL 15,000mL
Birthweight (g) 100 g 6000 g
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including the primary outcome and trial phase (pre-ran-
domisation, washout and comparison).
During the imputation process, the primary outcome
was captured by a three-category variable: baby born
SGA and detected by antenatal ultrasound, baby born
SGA and not detected by ultrasound, and baby not born
SGA. This three-category variable was imputed like any
other during the imputation process, but the primary
outcome finally used for analysis was calculated from its
imputed components (e.g. maternal weight, neonatal
birthweight, ethnicity). This approach was taken because
we needed to use the primary outcome as a predictor of
other variables in the imputation process but it was not
feasible to repeatedly and instantly passively impute the
primary outcome because identification of a baby as
SGA by customised centiles at birth, and by antenatal
ultrasound, requires calculations of centiles that could
only be done manually using a ‘macro’ (no direct for-
mula available).
Variables were imputed within cluster wherever pos-
sible, as characteristics of women and clinical processes
were expected to vary between clusters. Parity, maternal
height and maternal weight were imputed across clus-
ters, because some clusters had high levels of missing
data (and for each factor one site had no data) and the
rates were not expected to vary widely between clusters.
For one site, parity was only available as a binary vari-
able (nulliparous or multiparous) but an ordinal variable
was required. Parity was imputed using the common set
of predictors and, at this site, predicted parity values of
zero for women known to be multiparous were replaced
with a pre-specified value of ‘one’.
Ethnicity had high rates of missing data at some sites
but was imputed within cluster nevertheless because this
factor was known to vary strongly across sites. The full
list of variables imputed, whether imputed within or
across clusters, and the predictors used for their imput-
ation are summarised in Additional File 3.
Summary statistics from the imputed dataset were
compared to the equivalent summary statistics from the
observed data.
All assumptions and processes used were discussed
and approved by the joint Trial Steering and Data Moni-
toring Committee.
Results
The final data resource comprised data on 182,052 ba-
bies from 178,350 pregnancies in 165,397 unique
women. It was not possible to obtain one data type (hos-
pital administrative data) at one site at either time point;
hence, the final data resource was derived from 102
datasets out of a potential 104 datasets (four datasets
across two time periods at 13 research sites). Two other
datasets (ultrasound data from one site in both time
periods) had to be augmented with manually collected
data, since the local radiology software did not support
electronic reporting at scale, during the pre-
randomisation and implementation washout trial phases.
The data request for the first download was submitted
in February 2018 and the last research site supplied data
for this download request in February 2019. The second
download request was initiated in April 2019 and the
last dataset was collected 6 months later, in October
2019.
Pseudonymisation simulation
A simulation of 100,000 records using different maternal
identifiers and random numbers produced a non-
duplicated study ID with the fourth iteration (Table 2).
Maternal NHS number and DOB were chosen as the
identifiable variables due to low missingness and high
reliability. The final tool (test round 4) created a 20-
character study identification string from two maternal
identifiable variables (NHS number and DOB) where the
same pseudonym was always generated for the same
patient.
Of the 165,397 unique women, 705 did not have key
information required to generate an automated study
pseudonym and so were given a manually produced ID.
It is important to note that this manually produced ID
denotes a unique pregnancy; the same woman would
not be given the same ID if she had more than one birth
in the whole trial period.
Data quality—initial assessment
The data from maternity and neonatal EPR systems were
provided in wide format (one row per baby born). The
data from ultrasound and hospital administrative EPR
systems were always provided in long format (one row
per scan, appointment or hospital admission).
Common problems with the datasets obtained follow-
ing the first request were:
1. Missing variables which were key to the reporting
of the trial primary outcome or secondary
outcomes. This triggered a request for an amended
data download (at 6 of total 13 sites).
2. Duplicated records, which had to be distinguished
from records for multiple births. The ultrasound
data were used to clarify whether the pregnancy
was a singleton pregnancy (5 of 13 sites).
3. Data reports produced on a per-pregnancy rather
than per-baby basis, i.e. for women reported to have
had a multiple birth, one record would be expected
per baby born but often only the record for the
first-born baby was provided. This triggered a re-
quest for an amended report (2 sites).
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Where problems persisted with the second request for
data, it was usually because particular variables were not
routinely collected in the EPR.
The results of assessment for variable availability, me-
dian and range of completeness for some of the variables
which were key to calculating the primary outcome of
this trial (antenatal diagnosis of small growth status at
birth by customised and population-derived birthweight
centiles) are displayed in Table 3. The number of vari-
ables which were completely missing improved following
modified or clarified data requests for the second down-
load. The median completeness where the variable was
available did not change between data requests, but the
range widened in the second request, caused by avail-
ability of more variables, but with lower levels of
completeness.
Data harmonisation
The 22 EPR systems from which the raw data were
sourced are listed in Table 4. The neonatal data were
the only data type with a single EPR system source, this
was reflected in the consistent formats of the data
provided.
Data linkage
One hundred percent of study IDs from the linked (neo-
natal, ultrasound and activity) datasets matched with
study IDs from the maternal dataset because the IDs in
the linked datasets were derived from the maternal data-
set. The percentage of pregnancy IDs in the maternity
dataset which were linked with the other three datasets
are presented in Fig. 5. The linkage rate for maternity
with the neonatal dataset was low because babies only
have neonatal records when admitted to neonatal care
(e.g. preterm or born in poor condition). The linkage
rate of the maternity and activity dataset was affected by
one trial site which was unable to provide activity data
for any of their women. The linkage rate between the
maternity and ultrasound or activity datasets was not ex-
pected to be 100% because not all women who give birth
in a maternity unit had antenatal care in the same ma-
ternity unit (they may have received either no antenatal
care, or antenatal care elsewhere).
Final assessment of data quality
Levels of missing data for key variables required to cal-
culate the trial primary outcome were compared across
the linked dataset, following application of the outlier
policy, comparing trial arms at two trial phases (pre-ran-
domisation and trial comparison phases). The findings
are summarised in Table 5. For neonatal sex and birth
weight, there was very little missing data, there was more
missing data for maternal BMI, despite infilling missing
values in the maternity dataset with data from the ultra-
sound dataset. For variables with notable levels of miss-
ing data, there was variation between trial arms and the
Table 2 Refinement of the pseudonymisation tool
Test round Maternal data components used Study ID format Study ID length Duplicates
1st DOB, DOD, NHS number ##########
e.g.1234567890
10 18,382/100000
2nd DOB, DOD, NHS number ############
e.g. 123456789012
12 18,382/100000
3rd DOB, DOD, NHS number, check digit ###############XXX
e.g. 123456789012345ABC
18 21/100000
4th DOB, NHS number, check digit, random component with seed ###################X
e.g. 1234567891234567891A
20 0/100000
DOB date of birth, DOD date of delivery (of neonate), ID identifier, NHS National Health service
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period of data collection. Those allocated to the control
arm were more likely to have missing BMI data than
those in the intervention arm with this difference being
more marked in the trial comparison phase as the extent
of missingness decreased more in the intervention than
control arm over time. By contrast ethnicity was more
likely to be missing in the intervention arm than control
arm, but the proportion with missing data for both of
these variables decreased between the pre-randomisation
and trial comparison phases. In the pre-randomisation
phase, missing parity data was high (11–15%) in both of
the trial arms, this was because we requested parity as
an integer (as required to calculate our primary out-
come), but it was often only supplied as categorical (nul-
liparous/multiparous). Nulliparity can easily be
converted to parity = 0, but multiparity cannot. These
between randomised arm differences in missing data
could influence the main trial results and highlight the
importance of appropriate methods for dealing with
missing data.
Table 6 shows the distributions for variables that are
required for the calculation of the primary outcome,
comparing observed data and imputed data by each of
the intervention arms. Notably, the proportion of
Table 4 EPR systems used at sites for each data type
Maternity EPR system Ultrasound EPR
system



























Fig. 5 Linkage rates between the maternity and linked datasets
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women coded as ‘white’ ethnicity increased during the
pre-randomisation phase in the intervention arm; this
was expected because one cluster randomised to the
intervention, at which the majority of the pregnant
women are white, had high levels of missing data on eth-
nicity during this time period; this was corrected by the
time the trial comparison phase data were collected. The
proportion of multiparous women increased in the im-
puted data for the control arm of the trial during both
time periods, this was also expected because one control
arm cluster only provided information on nulliparity
(converted to parity = 0) or multiparity, as a binary value.
Parity was therefore only imputed for multiparous
women because we knew they had had a baby previ-
ously, but not how many. All other summary estimates
remained similar.
Discussion
Through this manuscript, we have outlined the data col-
lection and management strategies of the DESiGN Trial,
a randomised cluster-control trial which set out to col-
lect quantitative data solely from electronic patient re-
cords. We have shown that this method of data
collection is feasible and likely to be cost-effective. It
would have been much more expensive to collect the
same data (e.g. maternal age, weight, height, ethnicity
and infant outcomes) on ~ 180,000 pregnancies by
employing and training research midwives or research
assistants to collect the data in each hospital.
The use of EPR is not without challenges; we have
demonstrated that it requires appropriate resources to
maximise data completeness and quality. This was im-
proved by having planned an initial data download,
Table 5 Levels of missing data for key variables after the second data download, comparing trial phases
Pre-randomisation phase Trial comparison phase
Control Intervention Control Intervention
Maternal height 25.0% 11.0% 20.7% 3.0%
Maternal weight 15.3% 21.6% 12.0% 12.9%
Ethnicity 3.7% 14.1% 3.1% 7.1%
Parity 11.1% 15.2% 15.1% 7.4%
Neonatal sex 0.01% 0.1% 0.1% 0.5%
Neonatal birthweight 0.1% 0.3% 0.3% 0.5%
Gestational age 0.2% 4.8% 1.3% 3.8%
Table 6 Comparison of summary statistics between trial phases and intervention allocation
Pre-randomisation phase Trial comparison phase


















































White (%) 62.4% 62.8% 46.9% 50.2% 62.4% 62.7% 50.2% 50.6%
Black (%) 16.6% 16.2% 12.4% 11.8% 15.4% 15.1% 10.8% 10.9%
Asian (%) 13.4% 13.3% 27.1% 24.8% 13.5% 13.5% 25.2% 24.6%
Mixed (%) 2.2% 2.1% 1.6% 1.6% 2.6% 2.6% 1.3% 1.3%
Other (%) 5.4% 5.5% 12.1% 11.6% 6.1% 6.1% 12.5% 12.6%
Parity (% multiparous) 49.4% 53.7% 46.8% 46.5% 48.8% 52.5% 48.8% 51.6%


















Neonatal gestational age at birth in
weeks (median [IQR])
40 [39, 41] 40 [39, 41] 40 [39, 41] 40 [39, 41] 40 [39, 41] 40 [39, 41] 40 [39, 41] 40 [39, 41]
aFive categories of ethnicity presented here for brevity, but ethnicity imputed according to categories used by the foetal/neonatal weight customised centile
calculator, e.g. British European, Central African, Chinese, Mixed Asian-European
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followed by a second later download. This allowed the
team to test and clarify the first data request and to
make improvements that benefited the pre-
randomisation data and the data for the two subsequent
trial phases. Furthermore, multiple imputation was es-
sential to manage the level of missing data from EPR. It
was reassuring to note that summary statistics generated
from the imputed dataset were generally concordant
with the summary statistics on observed data, differing
only where expected because of biases in the missing
data. Nevertheless, imputation is based on the untestable
missing-at-random assumption and is not guaranteed to
reduce bias even if the best possible set of predictors has
been chosen. We noted limited instances (reporting of
severe perineal trauma, or use of epidural during labour)
where missing data were clearly not missing at random,
and instead very likely to be negative values. For these,
we intend to simply treat missing as negative at analysis
as a pragmatic solution.
Another important challenge was in harmonising data
received in multiple formats (including free text), to be
used for the same purpose. This included heterogeneity
of variables names, types and values for the requested
data. This arose from the number of different EPR sys-
tems that were used for different datasets and was fur-
ther complicated by some trial sites changing EPR
system mid-trial. These issues were less problematic for
neonatal data, because Badgernet neonatal is an EPR sys-
tem which is used universally by neonatal units in the
UK, and ultrasound data from the two common EPR
systems (Astraia, Germany and Viewpoint, GE Health-
care, USA). This meant that a standardised data extrac-
tion query could be made at the start of the trial and
was adopted by all sites when downloading data (Bad-
gernet query available in Additional File 1). Our data
dictionary (Additional File 2), which provides details of
the raw and harmonised variable names, a description of
the ideal variable (cleaned) format and instructions on
how to re-categorise each categorical variable (from each
site) into the harmonised form, could also be extremely
helpful to others working in this field.
Recommendations for the use of EPR in RCTs
We have used our experience to provide the following
recommendations to researchers planning trials with a
similar EPR data acquisition method. For those consider-
ing using EPRs for pregnancy and perinatal research in
the UK, we hope that our dictionary will be of value and
have provided it in full in the annex.
We suggest discussion with potential trial sites, before
recruitment, regarding the required information specifi-
cation and timelines. This will confirm what data each
site is able to provide and makes sure that the researcher
and on-site data providers know what is expected of
each other.
An on-site local data coordinator (e.g. information
technology clinical lead) should be identified, who agrees
to take responsibility for liaising with colleagues regard-
ing the generation of reports is likely to expedite the
data request process.
We found generation and review of a ‘trial’ data down-
load early in the process very helpful, rather than waiting
to download all data at the end of the trial and recom-
mend this process to others. This enabled the trial team
to check that all required data was available, obtain a
more complete and accurate full data download at the
end of the trial and make plans for the data harmonisa-
tion process.
We recommend that future groups applying for re-
search funds using EPRs ensure that they are aware of
how different sources may record the same data in dif-
ferent ways. Ensure that there is adequate research fund-
ing for the on-site data coordinator and other staff
involved in providing EPRs as well as adequate funding
for the central management of the data, including har-
monisation and developing a dictionary.
Lessons for the future use of EPRs in trials
We used EPRs for DESIGN because we felt it was the
only feasible way of conducting a trial including ~ 180,
000 pregnancies across 13 maternity units. An alterna-
tive approach would have been to use a bespoke trial
database in each centre. However, we estimate that this
would have required a full-time paid member of research
staff at each unit for a minimum of 9 months. Further-
more, staff in the units thought that such an approach
would cause a significant burden on them and it could
therefore have affected recruitment. Another strategy
could have involved data collection using a national
reporting system such as the UK’s Hospital Episode Sta-
tistics or the UK’s new national Maternity Services Data
Set (neither MSDS version was available at the time of
planning the trial). Both national datasets have the
advantage of data which are already collected to a
data specification, which is the same regardless of the
site from which data were uploaded. However, the
use of these are currently limited by the granularity
of information included and the high rates of missing
information [16, 17].
As research aims to include more participants so that
results are more generalisable across populations and
statistical power is increased, we believe the future lies
in the greater use of EPRs in clinical trials. For this to
happen at scale, national datasets such as those de-
scribed above, need to be extended using unified data
specifications which are sufficiently detailed to collect
data required by common core outcome sets and with
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promotion of data collection quality standards. Estab-
lished examples of this are the Swedish Medical Birth
Register [2], Scottish Medical Record (e.g. SMR02 for
maternity records [18]) and the UK National Neonatal
Research Database (NNRD) [19]. The UK MSDS is less
established than these other examples. As patient re-
cords become increasingly switched to EPRs, with inher-
ent clinical coding for diagnosis and procedure codes as
well as baseline demographics and characteristics, the
quality of EPR data is expected to improve with a result-
ant quality impact on the ability to report outcomes in
clinical trials [20, 21].
Conclusions
We have demonstrated the feasibility of using EPR to
undertake an RCT of 180,000 pregnancies in a situation
where data management was complicated by there being
no unified EPR system across maternity units. We have
shared our experience and provide research recommen-
dations and a detailed data dictionary that will help
others in the UK undertaking research with EPRs across
maternity units and in non-maternity settings.
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